Hepatitis B virus vaccine in lymphoproliferative disorders: A prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant

European Journal of Haematology

Volumn 79, Issue 4, 2007, Pages 292-296

  Yaǧci, Münci ^a,b   Acar, Kadir ^a   Sucak, Gülsan Türköz ^a   Yamaç, Kadri ^a   Haznedar, Rauf ^a  

^a GAZI UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Chronic lymphoproliferative disorders; Granulocyte macrophage colony stimulating factor; Hepatitis B virus vaccine; Vaccine adjuvant

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HAIRY CELL LEUKEMIA; HEADACHE; HODGKIN DISEASE; HUMAN; IMMUNITY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; VACCINES, SYNTHETIC;

EID: 34548563839     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00912.x     Document Type: Article

References (20)

1. Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBs Ag carriers with hemato- oncological neoplasias treated with chemotherapy. Leuk Lymphoma 2003 44: 759 66.
2. Koff RS. Hepatitis A, hepatitis B and combination hepatitis vaccines for immunoprophylaxis: an update. Dig Dis Sci 2002 47: 1183 94.
3. Goyal S, Pai SK, Kelkar R, Advani SH. Hepatitis B vaccination in acute lymphoblastic leukemia. Leuk Res 1998 22: 193 5.
4. Yetgin S, Tunç B, Koç A, Toksoy HB, Ceyhan M, Karna G. Two booster dose hepatitis B virus vaccination in patients with leukemia. Leuk Res 2001 25: 647 9.
5. Somjee S, Pai S, Parikh P, Banavali S, Kelkar R, Advani SH. Passive active prophylaxis against Hepatitis B in children with acute lymphoblastic leukemia. Leuk Res 2002 26: 989 92.
6. Singh NP, Mandal SK, Thakur A, Kapoor D, Anuradha S, Prakash A, Kohli R, Agarwal SK. Efficacy of GM-CSF as an adjuvant to hepatitis B vaccination in patients with chronic renal failure-Results of a prospective randomized trial. Ren Fail 2003 25: 255 66.
7. Van Burik JH. Clinical approach to infections in the comprimised host. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave B, eds. Hematology Basic Principles and Practice. Philadelphia, PA: Elsevier, 2005: 75 85.
8. Hamilton JA, Anderson GP. GM-CSF biology. Growth Factors 2004 22: 225 31.
9. Hess G, Kreiter F, Kösters W, Deusch K. The effect of granulocyte-macrophage colony stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients. J Viral Hepat 1996 3: 149 53.
10. Anandh U, Bastani B, Ballal S. Granulocyte-macrophage colony stimulating factor as an adjuvant to hepatitis B vaccination in maintanance hemodialysis patients. Am J Nephrol 2000 20: 53 6.
11. Sasaki MG, Foccacia R, De Messias-Reason IJ. Efficacy of granulocyte-macrophage colony stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003 21: 4545 9.
12. Haznedar R, Yaǧci M. Lamivudine therapy for acute hepatitis B infection following peripheral blood stem cell transplantation. Am J Hematol 2002 69: 151.
13. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004 22: 927 34.
14. Yaǧci M, Acar K, Sucak GT, Aki Z, Bozdayi M, Haznedar R. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematological malignancies and preemptive therapy with nucleoside analogues. Leuk Lymphoma 2006 47: 1608 12.
15. Petrelli E, Balducci M, Pieretti C, Rocchi MBL, Clementi M, Manzin A. Lamivudine treatment failure in preventing fatal outcome of de novo severe acute hepatitis B in patients with haematological diseases. J Hepatol 2001 35: 823 6.
16. Kapoor D, Aggarwal SD, Singh NP, Thakur V, Sarin SK. Granulocyte- macrophage colony stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hep 1999 6: 405 9.
17. Evans TG, Schiff M, Graves B, Agosti J, Barritt ML, Garner D, Holley JL. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin Nephrol 2000 54: 138 42.
18. Hasan MS, Agosti JM, Reynolds KK, Tanzman E, Treanor JJ, Evans TG. Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony stimulating factor (rh-GM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine 1996 14: 1199 204.
19. Cruciani M, Mengoli C, Serpelloni G, Mazzi R, Bosco O, Malena M. Granulocyte-macrophage colony stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis. Vaccine 2007 25: 709 18.
20. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002 35: 1368 75.